Russell Investments Group Ltd. lowered its stake in Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 9.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 429,427 shares of the technology company’s stock after selling 45,840 shares during the quarter. Russell Investments Group Ltd.’s holdings in Cogent Biosciences were worth $13,750,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Knights of Columbus Asset Advisors LLC boosted its position in Cogent Biosciences by 11.0% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 55,666 shares of the technology company’s stock valued at $1,782,000 after purchasing an additional 5,510 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of Cogent Biosciences by 2.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 15,078 shares of the technology company’s stock worth $476,000 after purchasing an additional 405 shares during the last quarter. Pictet Asset Management Holding SA increased its position in shares of Cogent Biosciences by 18.8% during the 3rd quarter. Pictet Asset Management Holding SA now owns 2,842,776 shares of the technology company’s stock worth $90,990,000 after purchasing an additional 449,261 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Cogent Biosciences during the 3rd quarter worth approximately $284,000. Finally, Profund Advisors LLC raised its stake in shares of Cogent Biosciences by 30.7% during the 3rd quarter. Profund Advisors LLC now owns 60,425 shares of the technology company’s stock worth $1,935,000 after purchasing an additional 14,199 shares in the last quarter.
Cogent Biosciences Trading Down 0.3%
Shares of NASDAQ:COGT opened at $27.74 on Friday. Cogent Biosciences, Inc. has a 52-week low of $26.36 and a 52-week high of $43.73. The company has a market capitalization of $4.83 billion, a P/E ratio of -12.33 and a beta of 0.36. The company has a 50-day simple moving average of $30.84 and a 200 day simple moving average of $35.12. The company has a debt-to-equity ratio of 0.50, a quick ratio of 10.99 and a current ratio of 10.99.
Cogent Biosciences (NASDAQ:COGT – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The technology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). Sell-side analysts forecast that Cogent Biosciences, Inc. will post -2.37 earnings per share for the current year.
Analysts Set New Price Targets
Several research firms have recently commented on COGT. Wall Street Zen downgraded Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, September 5th. HC Wainwright raised their target price on shares of Cogent Biosciences from $55.00 to $56.00 and gave the company a “buy” rating in a research note on Monday, November 9th. Piper Sandler boosted their target price on shares of Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Friday, October 2nd. Finally, Wedbush reaffirmed an “outperform” rating and set a $55.00 price target on shares of Cogent Biosciences in a research report on Wednesday, September 16th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Cogent Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $53.57.
View Our Latest Stock Analysis on Cogent Biosciences
Cogent Biosciences Profile
Cogent Biosciences is a clinical-stage biotechnology company developing precision medicines for diseases driven by specific genetic mutations. Its research focuses on targeted therapies intended to address the underlying causes of these conditions. The company’s lead investigational medicine, bezuclastinib, is a selective inhibitor of the KIT protein. Cogent has studied it in clinical programs for systemic mastocytosis and gastrointestinal stromal tumors (GIST), conditions in which abnormal KIT signaling can play a role.
Featured Articles
- Five stocks we like better than Cogent Biosciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report).
Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
